If catheterization identifies multivessel disease amenable to bypass, which intervention should be considered before noncardiac surgery?

If catheterization identifies multivessel disease amenable to bypass, which intervention should be considered before noncardiac surgery?

• A. CABG
• B. PCI
• C. Medical therapy only
• D. Proceed to surgery without revascularization

Answer: (A)

When a patient facing noncardiac surgery has significant multivessel coronary disease that can be revascularized, addressing the coronary problem before the operation lowers the risk of perioperative heart attacks and death. In this scenario, bypass surgery to revascularize all the diseased vessels is the best option because it provides durable, comprehensive restoration of blood flow across multiple territories. It reduces the likelihood of ischemic complications during the upcoming noncardiac procedure. Compared with PCI, CABG is preferred for multivessel disease since it treats several vessels at once and isn’t as dependent on antiplatelet strategies that would delay or complicate noncardiac surgery. Medical therapy alone would leave substantial residual ischemia, maintaining a higher perioperative cardiac risk. Going straight to noncardiac surgery without revascularization keeps the patient at elevated risk given the extent of disease. In practice, if the noncardiac operation can be safely delayed, CABG is performed to revascu­larize, with subsequent timing of the planned surgery after adequate recovery from the bypass.

When a patient facing noncardiac surgery has significant multivessel coronary disease that can be revascularized, addressing the coronary problem before the operation lowers the risk of perioperative heart attacks and death. In this scenario, bypass surgery to revascularize all the diseased vessels is the best option because it provides durable, comprehensive restoration of blood flow across multiple territories. It reduces the likelihood of ischemic complications during the upcoming noncardiac procedure.

Compared with PCI, CABG is preferred for multivessel disease since it treats several vessels at once and isn’t as dependent on antiplatelet strategies that would delay or complicate noncardiac surgery. Medical therapy alone would leave substantial residual ischemia, maintaining a higher perioperative cardiac risk. Going straight to noncardiac surgery without revascularization keeps the patient at elevated risk given the extent of disease.

In practice, if the noncardiac operation can be safely delayed, CABG is performed to revascu­larize, with subsequent timing of the planned surgery after adequate recovery from the bypass.